JAK inhibitors have been the go-to treatment for people with myelofibrosis (MF). Despite successfully reducing MPN-related symptoms, currently approved JAK inhibitors are not known to significantly change the course of MF disease. Similar to essential thrombocythemia (ET) and polycythemia vera (PV), therapy in these conditions focus primarily on lowering the risk of cardiovascular and thromboembolic consequences; in individuals with reduced thrombosis risks, careful waiting is frequently employed. The creation of rationally tailored medicines, however, with the aim of not only managing illness problems but also potentially altering disease course, has resulted from a greater understanding of MPN biology.

Both as oral monotherapy and in combination with cetuximab, adagrasib exhibited antitumor activity in patients who had received prior treatment and had metastatic colorectal cancer with mutant KRAS G12C. In the group receiving combination therapy, the median response time was greater than 6 months. Reversible negative outcomes were frequent in both groups.

A mass measuring 4.8 cm by 5.0 cm by 3.9 cm was detected by transabdominal and transvaginal ultrasonography of the abdomen and pelvis. This mass was located along the posterior part of the right hepatic lobe. Following the clinic evaluation, there were two important questions to answer. Initially, was the adrenal tumor malignant or benign? Second, did the lesion secrete hormones?

Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Combination therapy with once-daily oral gonadotropin-releasing hormone-receptor antagonist relugolix plus estradiol and norethindrone acetate in a 12-week course resulted in a significant reduction in bleeding in more than 70% of those in the therapy arms versus less than 20% for the placebo groups.

In the US, only two emergency contraceptive methods have been FDA approved: oral levonorgestrel and oral ulipristal acetate. However, the copper IUD appears to be an order of magnitude more effective than the approved methods and so copper IUD is often used. But women prefer the levonorgestrel IUD. This study looked to compare the two IUDs as emergency contraceptives. Among 711 women randomized to copper versus levonorgestrel IUDs, pregnancy rates were 1 in 317 in the levonorgestrel group and 0 in 321, equating to non-inferiority for the levonorgestrel IUD.

She has been treating her IBS with bismuth subsalicylate. Her symptoms include shortness of breath, nausea, and vomiting. On exam, the patient is confused. Laboratory testing showed primary anion-gap metabolic acidosis, primary respiratory alkalosis, and a salicylate level 25x greater than the normal upper limit.